Literature DB >> 33969

Ethopropazine and benztropine in neuroleptic-induced parkinsonism.

G Chouinard, L Annable, A Ross-Chouinard, M L Kropsky.   

Abstract

In a 12-week controlled study ethopropazine was compared to benztropine in the treatment of parkinsonism induced by fluphenazine enanthate in 60 schizophrenic outpatients. Ethopropazine and benztropine were found to be equally effective in controlling parkinsonian symptoms and were as efficacious as procyclidine, their previous antiparkinsonian drug. However, benztropine treated patients had a significant increase in tardive dyskinesia compared to their condition during procyclindine treatment, and significantly more anxiety and depression than ethopropazine treated patients. This suggests that benztropine is not the anticholinergic drug of choice in the treatment of neuroleptic-induced parkinsonian symptoms, because of its more toxic central and peripheral atropinic effect.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 33969

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  10 in total

1.  Management of common adverse effects of antipsychotic medications.

Authors:  T Scott Stroup; Neil Gray
Journal:  World Psychiatry       Date:  2018-10       Impact factor: 49.548

2.  Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug.

Authors:  G Chouinard; D Boisvert; J Bradwejn
Journal:  Can Med Assoc J       Date:  1982-04-01       Impact factor: 8.262

Review 3.  Assessment of anti-psychotic drugs.

Authors:  A V Mackay
Journal:  Br J Clin Pharmacol       Date:  1981-03       Impact factor: 4.335

4.  Levomepromazine versus chlorpromazine in treatment-resistant schizophrenia: a double-blind randomized trial.

Authors:  Samarthji Lal; Joseph X Thavundayil; N P Vasavan Nair; Lawrence Annable; Ng M K Ng Ying Kin; Antoine Gabriel; George Schwartz
Journal:  J Psychiatry Neurosci       Date:  2006-07       Impact factor: 6.186

5.  Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment.

Authors:  G Chouinard; L Annable; A Ross-Chouinard; M Olivier; F Fontaine
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

6.  An early phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients.

Authors:  G Chouinard; L Annable
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

7.  Chronic molindone treatment: relative inability to elicit dopamine receptor supersensitivity in rats.

Authors:  E Meller
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

8.  Pimozide in the treatment of newly admitted schizophrenic patients.

Authors:  G Chouinard; L Annable
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  Absence of severe tardive dyskinesia in Hungarian schizophrenic out-patients.

Authors:  G Gardos; I Samu; M Kallos; J O Cole
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

Review 10.  Antipsychotic reduction and/or cessation and antipsychotics as specific treatments for tardive dyskinesia.

Authors:  Hanna Bergman; John Rathbone; Vivek Agarwal; Karla Soares-Weiser
Journal:  Cochrane Database Syst Rev       Date:  2018-02-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.